Literature DB >> 15888032

Progression of alloresponse and tissue-specific immunity during graft coronary artery disease.

Masashi Tanaka1, Monika Zwierzchoniewska, Golnaz K Mokhtari, Raya D Terry, Leora B Balsam, Robert C Robbins, Eugenia V Fedoseyeva.   

Abstract

Chronic rejection remains the major obstacle for long-term transplant survival. Both indirect alloresponse and tissue-specific autoimmunity have been implicated in its pathogenesis. The interrelationship between these two types of host anti-graft response remains poorly understood. We have developed an immunosuppression-free mouse model of graft coronary artery disease (GCAD), in which all FVB (H-2(q)) cardiac allografts placed into minor Ag (mHC)-mismatched DBA/1 (H-2(q)) hosts survived more than 112 days, and developed GCAD. We then examined the kinetics of both anti-mHC alloresponse and host autoimmunity against heart-specific antigen, cardiac myosin (CM). At 8 days post-transplantation, recipient mice showed minimal intragraft inflammation and apoptosis, and limited expansion of allo-specific T cells. In addition, we observed early production of anti-myosin IgG1 autoantibodies, which occurred in the absence of activated CM-specific T lymphocytes. By day 56, GCAD indices, the numbers of mHC- and CM-reactive T cells, and the levels of circulating allo- and CM-specific antibodies were all significantly increased. While host alloresponse was exhausted at 112 days post-transplant, T-cell reactivity against CM persisted. Our data suggest that both allo- and tissue-specific immunity might contribute to the induction of GCAD. They indicate that continual autoimmune response against graft tissue antigens may provide for GCAD sustenance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15888032     DOI: 10.1111/j.1600-6143.2005.00880.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

Review 1.  B cells in cardiac transplants: from clinical questions to experimental models.

Authors:  William M Baldwin; Marc K Halushka; Anna Valujskikh; Robert L Fairchild
Journal:  Semin Immunol       Date:  2011-09-19       Impact factor: 11.130

2.  T-cell depletion eliminates the development of cardiac allograft vasculopathy in mice rendered tolerant by the induction of mixed chimerism.

Authors:  S Uehara; C M Chase; R B Colvin; J C Madsen; P S Russell
Journal:  Transplant Proc       Date:  2006-12       Impact factor: 1.066

Review 3.  Non-MHC antigenic targets of the humoral immune response in transplantation.

Authors:  Qiuheng Zhang; Elaine F Reed
Journal:  Curr Opin Immunol       Date:  2010-09-15       Impact factor: 7.486

Review 4.  The importance of non-HLA antibodies in transplantation.

Authors:  Qiuheng Zhang; Elaine F Reed
Journal:  Nat Rev Nephrol       Date:  2016-06-27       Impact factor: 28.314

5.  Autoantibodies to vimentin cause accelerated rejection of cardiac allografts.

Authors:  Balakrishnan Mahesh; Hon-Sing Leong; Ann McCormack; Padmini Sarathchandra; Angela Holder; Marlene L Rose
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

6.  Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection.

Authors:  Naohiko Fukami; Sabarinathan Ramachandran; Deepti Saini; Michael Walter; William Chapman; G Alexander Patterson; Thalachallour Mohanakumar
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

7.  Immune responses to self-antigens (autoimmunity) in allograft rejection.

Authors:  Sabarinathan Ramachandran; Vijay Subramanian; Thalachallour Mohanakumar
Journal:  Clin Transpl       Date:  2012

8.  IL-13 signaling via IL-13Rα2 triggers TGF-β1-dependent allograft fibrosis.

Authors:  Stefan M Brunner; Gabriela Schiechl; Rebecca Kesselring; Maria Martin; Saidou Balam; Hans J Schlitt; Edward K Geissler; Stefan Fichtner-Feigl
Journal:  Transplant Res       Date:  2013-10-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.